COYA 302's ALSTARS Phase 2 readout will determine whether Treg-based immunomodulation can alter ALS disease course in a randomized controlled trial

Bull

A positive readout would require COYA 302 to demonstrate a statistically significant slowing of functional decline, most likely measured by ALSFRS-R slope, versus placebo in a controlled trial — the first such evidence for Treg-based immunomodulation in ALS. This would validate the mechanistic hypothesis supported by the published longitudinal biomarker data correlating Treg activity with clinical outcomes, and would position COYA 302 for a pivotal trial with a potential Fast Track-facilitated accelerated review pathway, while also substantiating the Dr. Reddy's partnership value.

Bear

The most likely failure mode is an underpowered or noisy efficacy signal — ALS trials are notoriously difficult due to patient heterogeneity, rapid and variable disease progression rates, and the challenge of detecting meaningful slowing over a limited trial duration. A null or borderline result on the primary functional endpoint, even with favorable biomarker trends, would leave the core thesis unproven and likely require a larger, longer, and more expensive confirmatory study that the current cash runway may not support.